Bristol Myers Squibb Announces €5 Billion Senior Notes Offering
A massive financial move is on the horizon for Bristol Myers Squibb, as the company prepares to shake up the market with a substantial offering.
Bristol Myers Squibb (NYSE: BMY) has just revealed its plan to offer €5 billion in senior unsecured notes, a significant move that will undoubtedly capture the attention of investors. This offering, known as the "Offering," will be issued by the company's subsidiary, BMS Ireland Capital Funding Designated Activity Company, in five distinct tranches, each with its own unique terms and maturity dates.
Here's the breakdown:
- €750 million in 2.973% Notes due 2030
- €1.15 billion in 3.363% Notes due 2033
- €1.15 billion in 3.857% Notes due 2038
- €750 million in 4.289% Notes due 2045
- €1.2 billion in 4.581% Notes due 2055
But here's where it gets interesting: these notes will be fully guaranteed by Bristol-Myers Squibb Company on an unsecured senior basis. The company anticipates closing this offering on November 10, 2025, assuming all the usual conditions are met.
And there's more! Bristol Myers Squibb is also making a tender offer to buy back various series of its outstanding notes, using a combination of the offering's net proceeds and its own cash reserves, totaling approximately $3.0 billion. This tender offer is not contingent on the success of the main offering, adding a layer of flexibility to the company's strategy.
The offering is being managed by a group of prominent financial institutions, including Citigroup Global Markets Limited, Barclays Bank PLC, BNP PARIBAS, J.P. Morgan Securities, and Société Générale.
Investors can access the relevant documents by visiting the SEC's EDGAR system online. Alternatively, they can request these documents from the company or the underwriters directly. It's important to note that this press release is not an offer to sell or buy these notes; it's merely an announcement of the offering.
Forward-Looking Statements and Risks:
As with any significant financial move, there are forward-looking statements involved, which come with inherent risks and uncertainties. These statements are based on current expectations and projections, but various factors could cause actual results to differ. Bristol Myers Squibb highlights general market conditions, interest rate fluctuations, and access to capital markets as potential risks.
The company encourages investors to review its Annual Report on Form 10-K for 2024 and subsequent quarterly and current reports for a comprehensive understanding of these risks. And remember, forward-looking statements are just that—looking forward. They are not guarantees of future performance.
About Bristol Myers Squibb:
Bristol Myers Squibb is dedicated to transforming patients' lives through scientific innovation. Their mission is to develop and deliver groundbreaking medicines to help patients overcome serious diseases. With a focus on bold science, they are shaping the future of medicine and patient care.
